Advances in liver cancer antibody therapies: A Focus on glypican-3 and mesothelin

BioDrugs

Volumn 25, Issue 5, 2011, Pages 275-284

  Ho, Mitchell ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Amatuximab; GC 33; Glypican 3 inhibitors; Liver cancer; Megakaryocyte potentiating factor inhibitors; Monoclonal antibodies

Indexed keywords

AMATUXIMAB; ANTINEOPLASTIC AGENT; FURIN; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; GLYPICAN 3; HUMAN MONOCLONAL ANTIBODY; IMMUNOTOXIN; INTERLEUKIN 6; MESOTHELIN; SONIC HEDGEHOG PROTEIN; SORAFENIB; WNT PROTEIN;

BILE DUCT CARCINOMA; CANCER CHEMOTHERAPY; CANCER GROWTH; CELL GROWTH; CELL PROLIFERATION; CELL SURFACE; CYTOKINE RELEASE; GENE IDENTIFICATION; GENE MUTATION; LIVER CELL CARCINOMA; MELANOMA; MOLECULARLY TARGETED THERAPY; NONHUMAN; NUCLEOTIDE SEQUENCE; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; CARCINOMA, HEPATOCELLULAR; CHOLANGIOCARCINOMA; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYPICANS; GPI-LINKED PROTEINS; HUMANS; IMMUNOTHERAPY; LIVER NEOPLASMS; MICE; TUMOR MARKERS, BIOLOGICAL;

EID: 80053183510     PISSN: 11738804     EISSN: 1179190X     Source Type: Journal    
DOI: 10.2165/11595360-000000000-00000     Document Type: Review

References (83)

1. American Cancer Society. Liver cancer [online]. Available from URL: http:// www.cancer.org/Cancer/LiverCancer/DetailedGuide/index [Accessed 2011 Sep 6]
2. Ho M, Kim H. Glypican-3: a new target for cancer immunotherapy. Eur J Cancer 2011 Feb; 47 (3): 333-8
3. Kojima T, Oh-eda M, Hattori K, et al. Molecular cloning and expression of megakaryocyte potentiating factor cDNA. J Biol Chem 1995 S ep 15; 270 (37): 21984-90
4. Chang K, Pastan I. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci U S A 1996 Jan 9; 93 (1): 136-40 (Pubitemid 26041483)
5. Hassan R, Ho M. Mesothelin targeted cancer immunotherapy. Eur J Cancer 2008 Jan; 44 (1): 46-53 (Pubitemid 350262830)
6. Ordó ñ ez NG. Application of mesothelin immunostaining in tumor diagnosis. Am J Surg Pathol 2003 Nov; 27 (11): 1418-28 (Pubitemid 37315193)
7. Hassan R, Laszik ZG, Lerner M, et al. Mesothelin is overexpressed in pancreaticobiliary adenocarcinomas but not in normal pancreas and chronic pancreatitis. Am J Clin Pathol 2005 Dec; 124 (6): 838-45 (Pubitemid 41740183)
8. Yu L, Feng M, Kim H, et al. Mesothelin as a potential therapeutic target in human cholangiocarcinoma. J Cancer 2010 Oct 1; 1: 141-9
9. Filmus J, Church JG, Buick RN. Isolation of a cDNA corresponding to a developmentally regulated transcript in rat intestine. Mol Cell Biol 1988 Oct; 8 (10): 4243-9
10. De Cat B, Muyldermans SY, Coomans C, et al. Processing by proprotein convertases is required for glypican-3 modulation of cell survival, Wnt signaling, and gastrulation movements. J Cell Biol 2003 Nov 10; 163 (3): 625-35 (Pubitemid 37429874)
11. Capurro MI, Shi W, Sandal S, et al. Processing by convertases is not required for glypican-3-induced stimulation of hepatocellular carcinoma growth. J Biol Chem 2005 Dec 16; 280 (50): 41201-6 (Pubitemid 41832174)
12. Hippo Y, Watanabe K, Watanabe A, et al. Identification of soluble NH2- terminal fragment of glypican-3 as a serological marker for early-stage hepatocellular carcinoma. Cancer Res 2004 Apr 1; 64 (7): 2418-23 (Pubitemid 38523895)
13. Capurro M, Wanless IR, Sherman M, et al. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology 2003 Jul; 125 (1): 89-97 (Pubitemid 36799110)
14. Matthews DJ, Goodman LJ, Gorman CM, et al. A survey of furin substrate specificity using substrate phage display. Protein Sci 1994 Aug; 3 (8): 1197-205 (Pubitemid 24278200)
15. Feng M, Kim H, Phung Y, et al. Recombinant soluble glypican 3 protein inhibits the growth of hepatocellular carcinoma in vitro. Int J Cancer 2011May 1; 128 (9): 2246-7
16. Pilia G, Hughes-Benzie RM, MacKenzie A, et al. Mutations in GPC3, a glypican gene, cause the Simpson-γolabi-Behmel overgrowth syndrom e. Nat Genet 1996 Mar; 12 (3): 241-7 (Pubitemid 26080081)
17. Cano-γauci DF, Song HH, Yang H, et al. Glypican-3-deficient mice exhibit developmental overgrowth and some of the abnormalities typical of Simpson- Golabi-Behmel syndrome. J Cell Biol 1999 Jul 12; 146 (1): 255-64 (Pubitemid 29349979)
18. Song HH, Shi W, Filmus J. OCI-5/rat glypican-3 binds to fibroblast growth factor-2 but not to insulin-like growth factor-2. J Biol Chem 1997 Mar 21; 272 (12): 7574-7 (Pubitemid 27137302)
19. Chiao E, Fisher P, Crisponi L, et al. Overgrowth of a mouse model of the Simpson-γolabi-Behmel syndrome is independent of IGF signaling. Dev Biol 2002 Mar 1; 243 (1): 185-206 (Pubitemid 34208413)
20. Paine-Saunders S, Viviano BL, Zupicich J, et al. Glypican-3 controls cellular responses to Bmp4 in limb patterning and skeletal development. Dev Biol 2000 Sep 1; 225 (1): 179-87
21. Song HH, Shi W, Xiang YY, et al. The loss of glypican-3 induces alterations in Wnt signaling. J Biol Chem 2005 Jan 21; 280 (3): 2116-25
22. Cheng W, Tseng CJ, Lin TT, et al. Glypican-3-mediated oncogenesis involves the insulin-like growth factor-signaling pathway. Carcinogenesis 2008 Jul; 29 (7): 1319-26
23. Capurro MI, Xiang YY, Lobe C, et al. Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling. Cancer Res 2005 Jul 15; 65 (14): 6245-54 (Pubitemid 40994410)
24. Capurro MI,Xu P, Shi W, et al. Glypican-3 inhibits Hedgehog signaling during development by competing with patched for Hedgehog binding. Dev Cell 2008 May; 14 (5): 700-11 (Pubitemid 351622615)
25. Capurro MI, Li F, Filmus J. Overgrowth of a mouse model of Simpson- Golabi-Behmel syndrome is partly mediated by Indian hedgehog.EMBORep 2009 Aug; 10 (8): 901-7
26. Midorikawa Y, Ishikawa S, Iwanari H, et al. Glypican-3, overexpressed in hepatocellular carcinoma, modulates FGF2 and BMP-7 signaling. Int J Cancer 2003 Feb 10; 103 (4): 455-65 (Pubitemid 36020219)
27. Lai JP, Sandhu DS, Yu C, et al. Sulfatase 2 up-regulates glypican 3, promotes fibroblast growth factor signaling, and decreases survival in hepatocellular carcinoma. Hepatology 2008 Apr; 47 (4): 1211-22 (Pubitemid 351547907)
28. Lai JP, Oseini AM, Moser CD, et al. The oncogenic effect of sulfatase 2 in human hepatocellular carcinoma is mediated in part by glypican 3-dependent Wnt activation. Hepatology 2010 Nov; 52 (5): 1680-9
29. Malinauskas T, Aricescu AR, Lu W, et al. Modular mechanism of Wnt signaling inhibition by Wnt inhibitory factor 1. Nat Struct Mol Biol. Epub 2011 Jul 10
30. Zittermann SI, Capurro MI, Shi W, et al. Soluble glypican 3 inhibits the growth of hepatocellular carcinoma in vitro and in vivo. Int J Cancer 2010 Mar 15; 126 (6): 1291-301
31. HsuHC, ChengW, Lai PL.Cloning and expression of a developmentally regulated transcript MXR7 in hepatocellular carcinoma: biological significance and temporospatial distribution. Cancer Res 1997 Nov 15; 57 (22): 5179-84 (Pubitemid 27498138)
32. Nakatsura T, Yoshitake Y, Senju S, et al. Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker. Biochem Biophys Res Commun 2003 Jun 20; 306 (1): 16-25 (Pubitemid 36629398)
33. Shirakawa H, Suzuki H, Shimomura M, et al. Glypican-3 expression is correlated with poor prognosis in hepatocellular carcinoma. Cancer Sci 2009 Aug; 100 (8): 1403-7
34. Yamauchi N, Watanabe A, Hishinuma M, et al. The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma. Mod Pathol 2005 Dec; 18 (12): 1591-8 (Pubitemid 41670658)
35. Yasuda E, Kumada T, Toyoda H, et al. Evaluation for clinical utility of GPC3, measured by a commercially available ELISA kit with Glypican-3 (GPC3) antibody, as a serological and histological marker for hepatocellular carcinoma. Hepatol Res 2010 May; 40 (5): 477-85
36. Ishiguro T, Sugimoto M, Kinoshita Y, et al. Anti-γlypican 3 antibody as a potential antitumor agent for human liver cancer. Cancer Res 2008 Dec 1; 68 (23): 9832-8
37. Nakano K, Orita T, Nezu J, et al. Anti-γlypican 3 antibodies cause ADCC against human hepatocellular carcinoma cells. Biochem Biop hys Res Commun2009 Jan 9; 378 (2): 279-84
38. Nakano K, Ishiguro T, Konishi H, et al. Generation of a humanized antiglypican 3 antibody by CDR grafting and stability optimization. Anticancer Drugs 2010 Nov; 21 (10): 907-16
39. Ishiguro T, Kinoshita Y, Sugimoto M, et al. Anti-γlypican3 antibody for treatment of human liver cancer [abstract no. A2426]. Proceedings of the 101st Annual Meeting of the AACR; 2010 Apr 17-21; Washington, DC
40. Takai H, Kato A, Kinoshita Y, et al. Histopathological analyses of the antitumor activity of anti-γlypican-3 antibody (GC33) in human liver cancer xenograft models: the contribution of macrophages. Cancer Biol Ther 2009 May; 8 (10): 930-8
41. Chugai Pharmaceutical. A phase I study of GC33 in advanced or metastatic liver cancer (hepatocellular carcinoma) [ClinicalTrials.gov identifier: NCT00746317]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2011 Jul 18]
42. Chugai Pharmaceutical. Study of GC33 and sorafenib in combination in advanced ormetastatic liver cancer (hepatocellular carcinoma ) [ClinicalTrials.gov identifier: NCT00976170]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2011 Sep 5]
43. Ho M. Targeting glypican-3 and mesothelin for liver cancer therapy. Proceedings of the 7th Annual Meeting of the PEGS; 2011 May 9-13; Boston (MA)
44. Chang K, Pastan I, Willingham MC. Isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesothelium. Int J Cancer 1992 Feb 1; 50 (3): 373-81
45. Ho M, Onda M, Wang QC, et al. Mesothelin is shed from tumor cells [letter]. Cancer Epidemiol Biomarkers Prev 2006 Sep; 15 (9): 1751 (Pubitemid 44497117)
46. Hellstrom I, Raycraft J, Kanan S, et al. Mesothelin variant 1 is released from tumor cells as a diagnostic marker. Cancer Epidemiol Biomarkers Prev 2006 May; 15 (5): 1014-20 (Pubitemid 43823532)
47. Ho M, Hassan R, Zhang J, et al. Humoral immune response to mesothelin in mesothelioma and ovarian cancer patients. Clin Cancer Res 2005 May 15; 11 (10): 3814-20 (Pubitemid 40685601)
48. Hellstrom I, Friedman E, Verch T, et al. Anti-mesothelin antibodies and circulating mesothelin relate to the clinical state in ovarian cancer patients. Cancer Epidemiol Biomarkers Prev 2008 Jun; 17 (6): 1520-6
49. Pastan I, Hassan R, Fitzgerald DJ, et al. Immunotoxin therapy of cancer. Nat Rev Cancer 2006 Jul; 6 (7): 559-65. Review (Pubitemid 43980544)
50. Hassan R, Bullock S, Premkumar A, et al. Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers. Clin Cancer Res 2007 Sep 1; 13 (17): 5144-9 (Pubitemid 47502082)
51. Kreitman RJ, Hassan R, Fitzgerald DJ, et al. Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P. Clin Cancer Res 2009 Aug 15; 15 (16): 5274-9
52. Hassan R, Cohen SJ, Phillips M, et al. Phase I clinical trial of the chimeric antimesothelin monoclonal antibody MORAb-009 in patients with mesothelinexpressing cancers. Clin Cancer Res 2010 Dec 15; 16 (24): 6132-8
53. Bera TK, Pastan I. Mesothelin is not required for normal mouse development or reproduction. Mol Cell Biol 2000 Apr; 20 (8): 2902-6 (Pubitemid 30183509)
54. Yin BW, Lloyd KO. Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16. J Biol Chem 2001 Jul 20; 276 (29): 27371-5
55. Bast Jr RC, Klug TL, St John E, et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 1983 Oct 13; 309 (15): 883-7 (Pubitemid 13014028)
56. Rump A, Morikawa Y, Tanaka M, et al. Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion. J Biol Chem 2004 Mar 5; 279 (10): 9190-8 (Pubitemid 38295982)
57. Gubbels JA, Belisle J, Onda M, et al. Mesothelin-MUC16 binding is a high affinity, N-γlycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors. Mol Cancer 2006 Oct 26; 5 (1): 50
58. Kaneko O, Gong L, Zhang J, et al. A binding domain on mesothelin for CA125/MUC16. J Biol Chem 2009 Feb 6; 284 (6): 3739-49
59. Xiang X, Feng M, Felder M, et al. HN125: a novel immunoadhesin targeting MUC16 with potential for cancer therapy. J Cancer 2011; 2: 280-91
60. Prieve MG, Moon RT. Stromelysin-1 and mesothelin are differentially regulated by Wnt-5a and Wnt-1 in C57mg mouse mammary epithelial cells. BMC Dev Biol 2003 Apr 7; 3: 2
61. Uehara N, Matsuoka Y, Tsubura A. Mesothelin promotes anchorageindependent growth and prevents anoikis via extracellular signal-regulated kinase signaling pathway in human breast cancer cells. Mol Cancer Res 2008 Feb; 6 (2): 186-93 (Pubitemid 351342406)
62. Li M, Bharadwaj U, Zhang R, et al. Mesothelin is a malignant factor and therapeutic vaccine target for pancreatic cancer. Mol Cancer Ther 2008 Feb; 7 (2): 286-96 (Pubitemid 351302523)
63. Bharadwaj U, Li M, Chen C, et al. Mesothelin-induced pancreatic cancer cell proliferation involves alteration of cyclin E via activation of signal transducer and activator of transcription protein 3. Mol Cancer Res 2008 Nov; 6 (11): 1755-65
64. Bharadwaj U, Marin-Muller C, Li M, et al. Mesothelin overexpression promotes autocrine IL-6/sIL-6R trans-signaling to stimulate pancreatic cancer cell proliferation. Carcinogenesis 2011 Jul; 32 (7): 1013-24
65. Chang K, Pai LH, Pass H, et al. Monoclonal antibody K1 reacts with epithelial mesothelioma but not with lung adenocarcinoma. Am J Surg Pathol 1992 Mar; 16 (3): 259-68
66. Ho M, Bera TK, Willingham MC, et al. Mesothelin expression in human lung cancer. Clin Cancer Res 2007 Mar 1; 13 (5): 1571-5 (Pubitemid 46450449)
67. Scholler N, Fu N, Yang Y, et al. Soluble member(s) of the mesothelin/ megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma. Proc Natl Acad Sci U S A 1999 Sep 28; 96 (20): 11531-6 (Pubitemid 29487415)
68. Chowdhury PS, Viner JL, Beers R, et al. Isolation of a high-affinity stable single-chain Fv specific for mesothelin from DNA-immunized mi ce by phagedisplay and construction of a recombinant immunotoxin with anti-tumor activity. Proc Natl Acad Sci U S A 1998 Jan 20; 95 (2): 669-74 (Pubitemid 28083801)
69. Chowdhury PS, Pastan I. Improving antibody affinity by mimicking somatic hypermutation in vitro. Nat Biotechnol 1999 Jun; 17 (6): 568-72 (Pubitemid 29262920)
70. Hassan R, EbelW, Routhier EL, et al. Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin. Cancer Immun 2007 Dec 19; 7: 20
71. Onda M, Willingham M, Nagata S, et al. New monoclonal antibodies to mesothelin useful for immunohistochemistry, fluorescence-activated cell sorting, Western blotting, and ELISA. Clin Cancer Res 2005 Aug 15; 11 (16): 5840-6 (Pubitemid 41170311)
72. Hassan R, Remaley AT, Sampson ML, et al. Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer. Clin Cancer Res 2006 Jan 15; 12 (2): 447-53 (Pubitemid 43166134)
73. Onda M, Nagata S, Ho M, et al. Megakaryocyte potentiation factor cleaved from mesothelin precursor is a useful tumor marker in the serum of patients with mesothelioma. Clin Cancer Res 2006 Jul 15; 12 (14 Pt 1): 4225-31
74. Shiomi K, Miyamoto H, Segawa T, et al. Novel ELISA system for detection of N-ERC/mesothelin in the sera of mesothelioma patients. Cancer Sci 2006 Sep; 97 (9): 928-32 (Pubitemid 44151275)
75. Feng Y, Xiao X, Zhu Z, et al. A novel human monoclonal antibody that binds with high affinity to mesothelin-expressing cells and kills them by antibodydependent cell-mediated cytotoxicity. Mol Cancer Ther 2009 May; 8 (5): 1113-8
76. Ho M, Feng M, Fisher RJ, et al. A novel high-affinity human monoclonal antibody to mesothelin. Int J Cancer 2011 May 1; 128 (9): 2020-30
77. Xiang X, Phung Y, Feng M, et al. The development and characterization of a human mesothelioma in vitro 3D model to investigate immunotoxin therapy. PLoS One 2011 Jan 31; 6 (1): e14640
78. Feng M, Zhang J, Anver M, et al. In vivo imaging of human malignant mesothelioma grown orthotopically in the peritoneal cavity of nude mice. J Cancer 2011 Mar 1; 2: 123-31
79. Zhang Y, Xiang L, Hassan R, et al. Synergistic antitumor activity of taxol and immunotoxin SS1P in tumor-bearing mice. Clin Cancer Res 2006 Aug 1; 12 (15): 4695-701 (Pubitemid 44297823)
80. Zhang Y, Xiang L, Hassan R, et al. Immunotoxin and Taxol synergy results from a decrease in shed mesothelin levels in the extracellular space of tumors. Proc Natl Acad Sci U S A 2007 Oct 23; 104 (43): 17099-104 (Pubitemid 350210998)
81. Hassan R, Broaddus VC, Wilson S, et al. Anti-mesothelin immunotoxin SS1P in combination with gemcitabine results in increased activity against mesothelin- expressing tumor xenografts. Clin Cancer Res 2007 Dec 1; 13 (23): 7166-71 (Pubitemid 350276903)
82. ZhangY, Pastan I.High shed antigen levels within tumors: an additional barrier to immunoconjugate therapy. Clin Cancer Res 2008 Dec 15; 14 (24): 7981-6
83. Zhang Y, Hansen JK, Xiang L, et al. A flow cytometry method to quantitate internalized immunotoxins shows that taxol synergistically increases cellular immunotoxins uptake. Cancer Res 2010 Feb 1; 70 (3): 1082-9